RxDoctor Payments Data

Kristie Jackson

Acute Care · Nashville, TNNPI 1891765970

Payments from drug & device makers

$1,919in general payments, 2019–2025

Across 80 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$622
  • Bayer$174
  • Novartis$145
  • Heartflow, Inc.$134
  • E.r. Squibb & Sons, L.L.C.$109
  • Boehringer Ingelheim$100
  • plus $635 from 17 others

What the payments were for

  • Food & beverage$1,919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,919 in reported general payments places this provider in the 80th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$61,928
Medicare patients
415
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$76,211
BrilintaTicagrelor33$21,102
XareltoRivaroxaban18$16,896
Prasugrel Hcl87$10,165
Repatha SureclickEvolocumab11$9,025
Ranolazine ErRanolazine40$3,789
ClopidogrelClopidogrel Bisulfate263$2,692
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$2,228
Nebivolol Hcl14$2,143
Metoprolol Succinate108$1,723
Losartan Potassium128$1,593
Ezetimibe34$1,529
Atorvastatin Calcium133$1,415
Amlodipine Besylate87$557
Spironolactone59$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$76,21190 claims
AstraZenecaBrilinta$76$21,10233 claims
Johnson & JohnsonXarelto$74$16,89618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 738 acute care providers in Tennessee.

Other acute care in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →